Citigroup
DMAC icon

Citigroup’s DiaMedica Therapeutics DMAC Stock Holding History

Citigroup’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.8K Buy
1,896
+1,032
+119% +$8.18K ﹤0.01% 4952
2025
Q4 		$6.88K Sell
864
-579
-40% -$4.33K ﹤0.01% 5167
2025
Q3 		$9.91K Sell
1,443
-7,936
-85% -$43K ﹤0.01% 5025
2025
Q2 		$36.6K Sell
9,379
-7,386
-44% -$28.8K ﹤0.01% 4912
2025
Q1 		$63.5K Sell
16,765
-21,709
-56% -$124K ﹤0.01% 4810
2024
Q4 		$209K Buy
38,474
+16,377
+74% +$77.2K ﹤0.01% 4387
2024
Q3 		$92.6K Buy
+22,097
New +$81.6K ﹤0.01% 4793
2022
Q2 		– Sell
-273
Closed -$1K – 6314
2022
Q1 		$1K Buy
+273
New +$774 ﹤0.01% 6153

Other funds holding DMAC

CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citigroup's DMAC Position: Q1 2026 in Review

Citigroup increased its DiaMedica Therapeutics (DMAC) stake by 119% in Q1 2026, buying an estimated $8.18K and bringing the position to 1,896 shares worth $12.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4952.

Citigroup first reported a position in DMAC in Q1 2022 and has held it in 8 quarters since. The position peaked at $209K in Q4 2024. 98 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

  • Citigroup held 1,896 shares of DiaMedica Therapeutics worth $12.8K as of Q1 2026.
  • Citigroup bought 1,032 DiaMedica Therapeutics shares in Q1 2026, an estimated $8.18K.
  • DiaMedica Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4952 holding.
  • Citigroup first reported a position in DiaMedica Therapeutics in Q1 2022 and has held it in 8 quarters since.
  • Citigroup's DiaMedica Therapeutics position peaked at $209K in Q4 2024.
  • 98 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.